Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 for moderate-to-severe hidradenitis suppurativa (extension after STS-BDB001-06)
CTR20210545Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BDB-001 in hidradenitis suppurativa (HS), sponsored by Staidson Biopharmaceutical. Started Mar 2021; status: completed.
02
Drugs
BDB-001
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20210545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210545.